RHÖN-KLINIKUM AG reported solid financial results for 2025, meeting its targets despite challenging health policy and economic conditions. The German hospital group treated 938,650 patients across its facilities, representing a 2.5% increase from the previous year, while consolidated revenues grew organically by 6.8% to €1,704.7 million.
Dr. Stefan Stranz, a member of the Board of Management, noted that the group's economic development remains positive given the tense situation facing hospitals in Germany. The company attributes part of its success to cooperation within the corporate group with ASKLEPIOS, which has been an important success factor in navigating an environment characterized by medical progress, increasing demand for high-quality care, and economic pressure.
Despite the end of legislative relief for higher energy prices and challenging cost structures for medical products and personnel expenses, the company maintained EBITDA of €105.9 million. Consolidated profit decreased to €36.3 million due to higher depreciation and impairment of fixed assets as well as declining interest rates. The Supervisory Board and Board of Management have proposed a dividend of €0.20 per share.
In 2025, RHÖN-KLINIKUM AG launched further clinic development measures and added new care offerings at all locations to expand outpatient and inpatient treatment. The two university locations in Gießen and Marburg combined their strengths in a joint breast center, setting a new standard in oncological care in Hesse. The company's financial stability enables targeted investments in medical high-tech, according to Dr. Gunther K. Weiß, another Board of Management member, who stated this sends a strong signal for the dynamic and technological development of their facilities.
The group made significant technological investments throughout 2025, including a new laboratory line in Giessen, new cardiac catheter technologies and a 3 Tesla magnetic resonance tomograph in Marburg, and a radiotherapy system for cancer treatment in Bad Berka. The company has opened a new chapter with photon technology, becoming the only hospital group with three photon counting computer tomographs of the latest generation in use, with further investments planned. The company's Annual Report 2025 is published on the Internet at https://www.rhoen-klinikum-ag.com.
For 2026, the group expects revenues of approximately €1.7 billion within a range of plus or minus 5%, with EBITDA projected between €110 million and €125 million. The company also monitors non-financial performance indicators including number of cases and cost weights, which are expected to see moderate increases compared to 2025. This forecast reflects heightened regulatory interference by the German legislator and political implementation of necessary hospital reform.
The outlook acknowledges considerable uncertainties related to global crises resulting in higher prices and supply chain issues, as well as potential further regulatory measures impacting the remuneration structure for medical services in 2026. As one of Germany's largest healthcare service providers with five specialized facilities and over 19,100 employees, RHÖN-KLINIKUM AG's strategic investments in technology and care structures demonstrate how established healthcare providers can navigate industry challenges while advancing medical capabilities.
